LIPELLA PHARMACEUTICALS INC. (LIPO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US53630L2097
LIPELLA PHARMACEUTICALS INC. financials
| Fiscal year | 2024 |
|---|---|
| Revenue | 536,357.00 USD |
| Operating income | -5.08 m USD |
| EBIT | -5.08 m USD |
| Net income | -5.02 m USD |
| Diluted EPS – continuing operations | -4.79 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About LIPELLA PHARMACEUTICALS INC.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobulins for the treatment of non-muscle invasive bladder cancer. Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania. On March 30, 2026, Lipella Pharmaceuticals Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Western District of Pennsylvania.
More stocks
- Cloudweb, Inc. (CLOW)
- Community Redevelopment Inc. (CRDV)
- Vestand Inc. (VSTD)
- Regen BioPharma Inc (RGBP)
- 22nd Century Group, Inc. (XXII)
- ScanTech AI Systems Inc. (STAI)
- Sleep Number Corp (SNBRQ)
- ADVENT TECHNOLOGIES HOLDINGS, INC. (ADNH)
- Banzai International, Inc. (PARA)
- Smart Powerr Corp. (CREG)
- Profusa, Inc. (PFSA)
- PHOENIX MOTOR INC. (PEVM)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.